Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sinco Pharmaceuticals Holdings Limited (6833.HK)
Chengdu, CN
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.53% | -1.57% | -0.53% | +10.59% | +1.62% | +6.21% | +0.00% | -42.15% | -68.14% | -71.08% | -76.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Advertising Agencies: +8.1%-26.1% Q4'25: -38.7% (vs Q4'23)
-
EPS growth Advertising Agencies: +38.8%-15.0% Q4'25: -55.4% (vs Q4'23)
-
FCF margin FCF growth · Advertising Agencies: +39.2%+6.5% Q4'25: +21.5% (vs Q4'23)
-
EBIT margin Advertising Agencies: +7.9%+3.6% Q4'25: +2.6% (vs Q4'23)
-
ROIC Advertising Agencies: +6.8%+10.7% ★ Q4'25: +16.2% (vs Q4'23)
-
Share dilution Advertising Agencies: +0.0%+0.0% Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Advertising Agencies: -1.31×1.96× ★ Q4'25: 1.52× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|
| Revenue |
806.72M
est: 1.50B (-46.1%)
|
952.96M
est: 1.82B (-47.7%)
|
| EBITDA |
-69.61M
est: 94.76M (-173.5%)
|
-206.65M
est: 115.36M (-279.1%)
|
| EBIT |
-161.17M
est: 87.86M (-283.4%)
|
-237.20M
est: 106.96M (-321.8%)
|
| Net Income |
-185.90M
|
-280.61M
|
| SGA |
153.18M
est: 114.55M (+33.7%)
|
325.02M
est: 139.45M (+133.1%)
|
| EPS |
-0.12
|
-0.17
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiangbin Huang | Executive Chairman | 7M | male |
| Min Jin | Chief Executive Officer | 2M | male |
| Zhijian Huang | Executive Vice Chairman | 1M | male |
| Shifeng Lei | Executive Director | 823.3K | male |
| Tao Zhang | President of Sichuan Sinco Pharmaceuticals Co. Ltd. | — | male |
| Yifan Li | Chief Financial Officer | — | male |
| Yunlu Peng | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6833.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
